Literature DB >> 25348184

Immune response of thalassemia major patients in Indonesia with and without splenectomy.

Teny T Sari1, Djajadiman Gatot, Arwin A P Akib, Saptawati Bardosono, Sri R S Hadinegoro, Alida R Harahap, Ponpon S Idjradinata.   

Abstract

AIM: to describe non-spesific and specific immune response profile in Indonesian thalassemia major with and without splenectomy.
METHODS: this study was held at Thalassaemia Centre, Cipto Mangunkusumo Hospital Jakarta on September 2013-February 2014. A comparative cross sectional study was conducted in healthy, thalassemia major aged more than 12 year and seronegative HIV. They were matched in age and sex for splenectomised and non-splenectomised groups, analysing the non-spesific immune response (neutrophil count and phagocytosis) and specific immune response (count and function of cellular immunity). Infection episodes were also analized as immune response in vivo parameter.
RESULTS: splenectomised thalassemia major showed increased neutrophil count but significantly decreased non-spesific immune response (neutrophil phagocytosis). Spesific immune response of splenectomised group presented significantly higher absolute lymphocyte, lymphocyte T, CD4+ and CD8+ counts compared to non-splenectomised thalassemia major (p<0.05). Ratio CD4+/CD8+ were similar in these groups. Serum marker of activated cellular imunity function (IL-2 and TNF-) were similar among two groups. Mild infection episodes on splenectomised and non-splenectomised group were 2.02 (ranged 0 to 12) times and 0.81 (ranged 0 to 8) times (p=0.004), respectively. Severe infection on splenectomised group were sepsis for 2 weeks and diarrhea for 1 week, whereas on non-splenectomised group was typhoid fever for 4 days.
CONCLUSION: there were significant differences on immune response among thalassemia major patients. Splenectomised thalassemia major showed a greater degree of susceptibility to infections than non-splenectomised thalassemia major.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25348184

Source DB:  PubMed          Journal:  Acta Med Indones        ISSN: 0125-9326


  7 in total

1.  Alteration of T Cell Subtypes in Beta-Thalassaemia Major: Impact of Ferritin Level.

Authors:  Batoul Pourgheysari; Leila Karimi; Pezhman Beshkar
Journal:  J Clin Diagn Res       Date:  2016-02-01

2.  Low IL-2 Expressing T Cells in Thalassemia Major Patients: Is It Immune Aging.

Authors:  Batoul Pourgheysari; Leila Karimi; Raihaneh Bagheri; Soleiman Kheiri
Journal:  Indian J Hematol Blood Transfus       Date:  2018-03-07       Impact factor: 0.900

3.  Hematological and biochemical evaluation of β-thalassemia major (βTM) patients in Gaza Strip: A cross-sectional study.

Authors:  Hani Ayyash; Mahmoud Sirdah
Journal:  Int J Health Sci (Qassim)       Date:  2018 Nov-Dec

Review 4.  The "Dialogue" Between Central and Peripheral Immunity After Ischemic Stroke: Focus on Spleen.

Authors:  Hongchen Yu; Yichen Cai; Aiqin Zhong; Yunsha Zhang; Junping Zhang; Shixin Xu
Journal:  Front Immunol       Date:  2021-12-16       Impact factor: 7.561

5.  Impaired neutrophil extracellular trap formation in β-thalassaemia/HbE.

Authors:  Rattanawan Thubthed; Sirikwan Siriworadetkun; Kittiphong Paiboonsukwong; Suthat Fucharoen; Kovit Pattanapanyasat; Jim Vadolas; Saovaros Svasti; Pornthip Chaichompoo
Journal:  Sci Rep       Date:  2022-02-04       Impact factor: 4.379

6.  Evaluation of immune system in patients with transfusion-dependent beta-thalassemia in Rasoul-e-Akram Hospital in 2021: A descriptive cross-sectional study.

Authors:  Fahime Ehsanipour; Pooya Faranoush; Mohammad Reza Foroughi-Gilvaee; Negin Sadighnia; Morteza Fallahpour; Mona Motamedi; Afsoon Zandi; Zahra Safaei; Ashkan Zandi; Mohammad Faranoush
Journal:  Health Sci Rep       Date:  2022-10-03

7.  Increased Risk of Hemorrhagic and Ischemic Strokes in Patients With Splenic Injury and Splenectomy: A Nationwide Cohort Study.

Authors:  Jiun-Nong Lin; Cheng-Li Lin; Ming-Chia Lin; Chung-Hsu Lai; Hsi-Hsun Lin; Chih-Hui Yang; Chia-Hung Kao
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.